Jessica Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jessica Wu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jan Smogorzewski
Division of Dermatology, Harbor-UCLA Medical Center, Torrance, California; Department of Medicine, The Lundquist Institute, Torrance, California; David Geffen School of Medicine at UCLA, Los Angeles, California
3 shared publications Janice E. Ma
Division of Dermatology Harbor‐UCLA Medical Center Torrance CA USA
1 shared publicationLadan Afifi
Division of Dermatology University of California Los Angeles Los Angeles CA USA
1 shared publication- Suzanne M. Sachsman
Division of Dermatology University of California Los Angeles Los Angeles CA USA
1 shared publication
Latest Publications
- 1 July 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (7) , 829-830
Diffuse subcutaneous nodules in a patient with human immunodeficiency virus (HIV)
- 1 July 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (7) , 829-830
Diffuse subcutaneous nodules in a patient with human immunodeficiency virus (HIV)
- 16 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (3) , e14883
Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases
Ustekinumab (STELARA®), a human monoclonal antibody directed against IL‐12 and IL‐23, is FDA‐approved to treat psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Increasing recognition of paradoxical skin reactions induced by older biologic therapies used for inflammatory bowel diseases (IBD), such as adalimumab and infliximab, has led to the investigation of ustekinumab for the treatment of the cutaneous and gastrointestinal manifestations of IBD. In addition, ustekinumab may show efficacy in treating paradoxical cutaneous reactions to tumor necrosis factor‐alpha (TNF‐α) inhibitors. A search of the Medline/PubMed database, with additional citations obtained from the references section of relevant articles, yielded 22 articles that were included in this review. Ustekinumab is a safe and effective option for treating the cutaneous manifestations of IBD, such as metastatic Crohn's disease and pyoderma gangrenosum. It is also an effective treatment for TNF‐α inhibitor‐induced paradoxical skin reactions such as psoriasis that do not remit spontaneously or with conventional treatment. Additional studies should focus on the optimal dosing of ustekinumab for dermatologic conditions beyond psoriasis.
- 16 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (3) , e14883
Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases
Ustekinumab (STELARA®), a human monoclonal antibody directed against IL‐12 and IL‐23, is FDA‐approved to treat psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Increasing recognition of paradoxical skin reactions induced by older biologic therapies used for inflammatory bowel diseases (IBD), such as adalimumab and infliximab, has led to the investigation of ustekinumab for the treatment of the cutaneous and gastrointestinal manifestations of IBD. In addition, ustekinumab may show efficacy in treating paradoxical cutaneous reactions to tumor necrosis factor‐alpha (TNF‐α) inhibitors. A search of the Medline/PubMed database, with additional citations obtained from the references section of relevant articles, yielded 22 articles that were included in this review. Ustekinumab is a safe and effective option for treating the cutaneous manifestations of IBD, such as metastatic Crohn's disease and pyoderma gangrenosum. It is also an effective treatment for TNF‐α inhibitor‐induced paradoxical skin reactions such as psoriasis that do not remit spontaneously or with conventional treatment. Additional studies should focus on the optimal dosing of ustekinumab for dermatologic conditions beyond psoriasis.
- 1 November 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (6) , e85-e86
Hyperpigmented atrophic lesions in a young girl
- 1 November 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (6) , e85-e86
Hyperpigmented atrophic lesions in a young girl
- 9 June 2020
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (2) , 606-612
Off-label studies on ruxolitinib in dermatology: a review
Ruxolitinib is a Janus kinase (JAK) inhibitor that is FDA-approved for the treatment of myelofibrosis, polycythemia vera, and acute graft-versus-host disease. Its use in treating various dermatologic diseases has been a topic of growing interest due to its favorable safety profile and targeted inhibition of several cytokines that perpetuate inflammatory skin conditions. The PubMed/MEDLINE and ClinicalTrials.gov databases were searched for literature on off-label uses of ruxolitinib in dermatology and ongoing trials studying its safety and efficacy. There is randomized controlled trial (RCT) evidence for the successful use of ruxolitinib in treating alopecia, atopic dermatitis, and psoriasis, with ongoing RCTs for its use in vitiligo. Smaller studies have confirmed the success of ruxolitinib in treating conditions such as dermatomyositis and hypereosinophilic syndrome, among others. No serious adverse effects were reported with the use of ruxolitinib in dermatology, but further research is needed to determine its efficacy, delivery route, and optimal dosing for treating dermatologic conditions.
- 9 June 2020
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (2) , 606-612
Off-label studies on ruxolitinib in dermatology: a review
Ruxolitinib is a Janus kinase (JAK) inhibitor that is FDA-approved for the treatment of myelofibrosis, polycythemia vera, and acute graft-versus-host disease. Its use in treating various dermatologic diseases has been a topic of growing interest due to its favorable safety profile and targeted inhibition of several cytokines that perpetuate inflammatory skin conditions. The PubMed/MEDLINE and ClinicalTrials.gov databases were searched for literature on off-label uses of ruxolitinib in dermatology and ongoing trials studying its safety and efficacy. There is randomized controlled trial (RCT) evidence for the successful use of ruxolitinib in treating alopecia, atopic dermatitis, and psoriasis, with ongoing RCTs for its use in vitiligo. Smaller studies have confirmed the success of ruxolitinib in treating conditions such as dermatomyositis and hypereosinophilic syndrome, among others. No serious adverse effects were reported with the use of ruxolitinib in dermatology, but further research is needed to determine its efficacy, delivery route, and optimal dosing for treating dermatologic conditions.